Kytopen: T-CURX GmbH Enters into Technology Access Agreement with Kytopen

Kytopen announces expansion of its partnership program into Europe with its agreement with T-CURX GmbH, a biotech company based in Würzburg, Germany.T-CURX, a clinically focused therapeutic company developing personalized immunotherapies, will have on-site access to Kytopen's Flowfect Tx cellular engineering platform.A critical deciding factor for T-CURX, was the Flowfect Tx platform proof of validation for GMP manufacturing of engineered cells at clinical and commercial scale.CAMBRIDGE, Mass. and WÜRZBURG, Germany, Feb. 13, 2025 /PRNewswire/ -- Kytopen Corp., a leader in providing non-viral, continuous flow cellular engineering technologies, and T-CURX GmbH ("T-CURX"), a leader in non-viral, transposon-based CAR-T manufacturing for the treatment of cancer, today announced the execution of a joint agreement providing T-CURX access to the Flowfect® cellular engineering technology through Kytopen's Technology Access Program ("TAP"). The signing of this most recent TAP agreement represents the expansion of Kytopen's program into Europe. By combining the Flowfect Tx platform with its proprietary transposon gene transfer technology, T-CURX seeks to overcome the hurdles in combatting solid tumors and cell therapy scale-up and foresees bringing a more potent and durable cell therapy to the clinic more rapidly....Full story available on Benzinga.com